Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Disruption of the Blood-Brain Barrier by MRI-guided Focused Ultrasound for the Enhanced Delivery of Chemotherapeutics and Bevacizumab in the Treatment of Glioblastoma Multiforme

EF 2014-15

Résumé
The blood brain barrier (BBB) presents a formidable challenge to the treatment of glioblastoma multiforme, the most aggressive and common malignant brain tumor. Current strategies to circumvent the barrier have been met with limited success and have even risked the well-being of patients due to their invasive nature. A newer methodology in recent development is magnetic resonance imaging-guided focused ultrasound (MRIgFUS). Unlike typical brain surgery, MRIgFUS creates very localized and temporary disruptions in the barrier - large enough to allow anti-cancer drugs to pass through, but small enough to allow for rapid healing within 24 hours. Effectively, this makes MRIgFUS capable of non-invasive surgery. MRIgFUS will be tested in two ways. In the first, it will be used to allow for the delivery of the anti-cancer drug doxorubicin, a highly effective chemotherapeutic that normally cannot pass the BBB. It will be compared to the current gold-standard, temozolomide, a drug that can pass the BBB, but is easily resisted by the cancer. It is hoped that, through MRIgFUS, current treatment standards will be re-assessed and drugs that were previously discarded will now be given a second chance to combat brain cancer. The second portion of this project aims at utilizing MRIgFUS to assist in the delivery of bevacizumab, an anti-cancer agent that works by increasing tumor oxygenation. This may seem counter-intuitive at first, but the increased oxygenation will allow for more free radicals to be formed inside tumor cells during radiotherapy. In essence, through being able to deliver this anti-cancer agent, tumor cells will become extra-sensitive to radiation, again setting the standard for radiologists to use MRIgFUS in their treatment regimens.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
331283
Name
Pasternak Maurice M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Disruption of the Blood-Brain Barrier by MRI-guided Focused Ultrasound for the Enhanced Delivery of Chemotherapeutics and Bevacizumab in the Treatment of Glioblastoma Multiforme
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bevacizumab; Blood-Brain Barrier; Doxorubicin; Focused Ultrasound; Glioblastoma Multiforme; Mri Guidance; Radiotherapy; Targetted Drug Delivery; Temozolomide; Vascular Normalization
Abstract
The blood brain barrier (BBB) presents a formidable challenge to the treatment of glioblastoma multiforme, the most aggressive and common malignant brain tumor. Current strategies to circumvent the barrier have been met with limited success and have even risked the well-being of patients due to their invasive nature. A newer methodology in recent development is magnetic resonance imaging-guided focused ultrasound (MRIgFUS). Unlike typical brain surgery, MRIgFUS creates very localized and temporary disruptions in the barrier - large enough to allow anti-cancer drugs to pass through, but small enough to allow for rapid healing within 24 hours. Effectively, this makes MRIgFUS capable of non-invasive surgery. MRIgFUS will be tested in two ways. In the first, it will be used to allow for the delivery of the anti-cancer drug doxorubicin, a highly effective chemotherapeutic that normally cannot pass the BBB. It will be compared to the current gold-standard, temozolomide, a drug that can pass the BBB, but is easily resisted by the cancer. It is hoped that, through MRIgFUS, current treatment standards will be re-assessed and drugs that were previously discarded will now be given a second chance to combat brain cancer. The second portion of this project aims at utilizing MRIgFUS to assist in the delivery of bevacizumab, an anti-cancer agent that works by increasing tumor oxygenation. This may seem counter-intuitive at first, but the increased oxygenation will allow for more free radicals to be formed inside tumor cells during radiotherapy. In essence, through being able to deliver this anti-cancer agent, tumor cells will become extra-sensitive to radiation, again setting the standard for radiologists to use MRIgFUS in their treatment regimens.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pasternak, Maurice M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~